Clinical Trials Study
Copyright ©The Author(s) 2024.
World J Clin Cases. Aug 6, 2024; 12(22): 5016-5023
Published online Aug 6, 2024. doi: 10.12998/wjcc.v12.i22.5016
Table 1 Characteristics of study patients
Characteristics
Group-I
Group-II
Group-III
P value
n = 110
n = 42
n = 16
I vs II
II vs III
Age (years; mean ± SD) 51.36 ± 19.7258.15 ± 16.9161.81 ± 22.650.17410.2013
Sex (M/F) 56/5427/1511/50.5975> 0.9999
Smoking, n (%)72 (65.45)27 (64.28)11 (68.75)0.60120.5812
WBC (× 109/L)10.87 ± 4.0211.13 ± 4.3813.01 ± 4.180.06730.2015
CRP (mg/L)36.76 ± 28.1181.23 ± 51.18132.77 ± 64.830.00570.0013
PCT (μg/L)0.77 ± 1.421.01 ± 2.122.98 ± 3.43< 0.0001< 0.0001
PSI score76.12 ± 28.94101.3 ± 40.51121.8 ± 48.21< 0.00010.0002
CURB-65 score0.00820.0013
0-173202 
232135 
3-5599 
Pathogen checked 
Bacteria28196 
Virus1175 
Atypical pathogen3110 
Mixed pathogen1541 
Unknown25114 
Activin A (ng/mL)11.92 ± 8.2117.61 ± 5.3525.33 ± 7.370.0006< 0.0001
Table 2 Areas under the curve and thresholds for predicting hospital mortality in patients with community-acquired pneumonia

Threshold
Sensitivity (%)
Specificity (%)
AUC
P value
95%CI
CRP> 8480.6559.120.7220.00080.587-0.811
PCT> 2.3157.3687.910.6820.00050.601-0.824
CURB-65> 173.6681.020.846< 0.00010.725-0.914
PSI> 10876.0880.360.85< 0.00010.748-0.937
Activin A (ng/mL)> 1983.2781.440.854< 0.00010.787-0.941
Table 3 Prognostic effect of activin A for hospital mortality in Cox proportional hazards regression analysis
Variables
Univaritate analysis
Multivaritate analysis
HR (95%CI)
P value
HR (95%CI)
P value
Age1.112 (1.000-1.064)0.0624 
Sex0.881 (0.343-2.106)0.5751 
Smoking1.113 (0.551-2.471)0.9931 
WBC1.127 (0.931-1.202)0.3428 
CRP1.103 (1.012-1.206)0.0661 
PCT1.045 (1.023-1.057)0.0232 
CURB-652.157 (1.512-3.104)< 0.0001 
PSI1.018 (1.005-1.037)< 0.00011.024 (1.012-1.047)< 0.0001
Activin A1.024 (1.011-1.028)< 0.00011.028 (1.014-1.031)< 0.0001